ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2018
The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study.Journal of health, population, and nutrition · 2025Article
- Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model.Cost effectiveness and resource allocation : C/E · 2024Article
- A systematic literature review on direct and indirect costs of triple-negative breast cancer.Cost effectiveness and resource allocation : C/E · 2023Review
- Economic burden of breast cancer: a case of Southern Iran.Cost effectiveness and resource allocation : C/E · 2023Article
- A systemmatic literature review on indirect costs of women with breast cancer.Cost effectiveness and resource allocation : C/E · 2022Review
- Cost of breast cancer care in low- and middle-income countries: a scoping review protocol.JBI evidence synthesis · 2021Article
- Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review.The oncologist · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND
methodsThis is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis.
resultsThe estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative.
conclusionOverall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.